Home › Funds › Elmind Capital, LP › AMLX

Elmind Capital, LP position in AMLX

AMYLYX PHARMACEUTICALS INC · Health Care

Elmind Capital, LP reported holding 894,760 shares of AMLX (AMYLYX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$26.0M, representing 6.45% of its reported portfolio and ranking #6 among its reported holdings. Elmind Capital, LP has disclosed AMLX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

Latest position (Q3 2026)894.76K sh
Reported value held$26.04M
Portfolio Weight6.45%
First reportedQ4 2025
Last changeAdd
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How Elmind Capital, LP's AMLX position evolved

Elmind Capital, LP first disclosed a stake in AMLX in Q4 2025 at 112,000 shares (US$1.4M). The position peaked in Q3 2026 at 894,760 shares, worth US$26.0M. Across 4 filings, Elmind Capital, LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 894,760 shares valued at US$26.0M — an increase of 782,760 shares quarter over quarter.. Notable position changes include a 699% increase in Q3 2026 (shares fell 4% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2025 112.00K $1.35M New
Q1 2026 112.00K $1.56M Hold
Q2 2026 112.00K $2.01M Hold
Q3 2026 894.76K $26.04M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About AMLX and 13F data

AMLX (AMYLYX PHARMACEUTICALS INC) is a Health Care company. 53 other funds we track also report a position in AMLX — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$307.7M), TCG Crossover Management, LLC (US$181.7M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$158.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding AMLX

All AMLX fund holders →

FAQ

How long has Elmind Capital, LP held AMLX?

Elmind Capital, LP has disclosed AMLX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

What is Elmind Capital, LP's current position in AMLX?

As of Q3 2026, Elmind Capital, LP holds 894.76K shares of AMLX (AMYLYX PHARMACEUTICALS INC), valued at $26.04M, representing 6.45% of its reported portfolio and ranking #6.

Has Elmind Capital, LP been buying or selling AMLX?

In the latest 13F filing (Q3 2026), Elmind Capital, LP increased its position in AMLX. The position peaked in Q3 2026 at 894.76K shares.

Which other funds hold AMLX?

Other major institutional holders of AMLX include PERCEPTIVE ADVISORS LLC, TCG Crossover Management, LLC, DRIEHAUS CAPITAL MANAGEMENT LLC, among 53 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.